Net margin is calculated as Net Income divided by its Revenue. Ortin Global's Net Income for the
three
months ended in Mar. 2026 was ₹-0.09 Mil. Ortin Global's Revenue for the
three
months ended in Mar. 2026 was ₹0.34 Mil. Therefore, Ortin Global's net margin for the quarter that ended in Mar. 2026 was -27.03%.
The historical rank and industry rank for Ortin Global's Net Margin % or its related term are showing as below:
BOM:539287'
s Net Margin % Range Over the Past 10 Years
Min: -736.72 Med: -0.92 Max: 11.58
Current: -736.72
BOM:539287's Net Margin % is ranked worse than 96.03% of 957
companies
in the Drug Manufacturers industry
Industry Median: 5.58
vs BOM:539287: -736.72
Ortin Global (BOM:539287) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Ortin Global Net Margin % Related Terms
Ortin Global Net Margin % Historical Data
* Premium members only.
The historical data trend for Ortin Global's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Ortin Global's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ortin Global Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ortin Global's Net Margin % distribution charts can be found below:
* The bar in red indicates where Ortin Global's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ortin Global (BOM:539287) has a Net Margin % of -27.03% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Ortin Global and its competitors. According to the industry distribution chart, Ortin Global ranks #919 out of 957 companies in the Drug Manufacturers industry, placing it in the top 96%.
Is Ortin Global's Net Margin % too high?
Ortin Global's current Net Margin % is -27.03%. Based on the distribution chart, Ortin Global ranks #919 out of 957 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Ortin Global has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ortin Global's Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Ortin Global ranks #919 out of 957 companies for Net Margin %. This places Ortin Global in the lower half of its industry. The industry median Net Margin % is 5.58. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.58, based on 957 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Ortin Global and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ortin Global's current Net Margin % is -27.03%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ortin Global stock overvalued right now?
Based on GuruFocus' analysis, Ortin Global (BOM:539287) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹2.54, compared to a current price of ₹16.48 — trading 548.8% above its estimated fair value. The current Net Margin % is -27.03%. Ortin Global's overall GF Score™ is 42/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Ortin Global (BOM:539287), the current Net Margin % is -27.03% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ortin Global (BOM:539287) Overvalued in 2026?
Based on GuruFocus' analysis, Ortin Global stock appears to be overvalued.
The current stock price of ₹16.48 is trading 548.8% above its estimated GF Value™ of ₹2.54.
GuruFocus considers Ortin Global to be Significantly Overvalued.
Key valuation signals for BOM:539287:
Net Margin %: -27.03%
GF Value™: ₹2.54 vs. price of ₹16.48 (548.8% above fair value)
No single metric tells the full story. See the BOM:539287 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ortin Global Ltd is an Indian company engaged in the manufacturing and trading of Pharmaceuticals, Drugs, and Intermediates. Its formulations include anti-diabetics, anti-allergics, anti-anginal and cardiovascular, sedatives and tranquilisers, anti-helminthics, analgesics and antipyretics, antibiotics, antifungal, cephalosporins, and others. Some of its API intermediates include Ciprofloxacin, Tramadol, Efavarenz, Lamivudine, Zidovudine, Nevirapine, Lopinavir, Fluconazole, Triclabendazole, Omeprazole, and others. Additionally, the company is also involved in the real estate business.
42GF Score
Get the complete analysis for BOM:539287
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:539287 has been successfully added to your 
